Continuous delivery of drugs to the eye offers major alternative to the already existing animal models. Hence, advantages over the conventional ocular therapies that an attempt has been made in the present study to evaluate involve administration of drug solutions or suspensions as the antimicrobial efficacy of ciprofloxacin hydrochloride eye drops. Eye drop administration often results in poor (CPH) ocular inserts of polyvinyl alcohol (PVA) using an bioavailability and therapeutic response due to rapid prein vitro microbiological model and correlate the results corneal elimination of the drug and is also associated with with the in vitro release data. patient compliance problems 1,2 . An ocular sustained release dosage form would ideally eliminate these
MATERIALS AND METHODS
problems by providing steady pre-corneal drug levels for 12-24 h periods.
Ciprofloxacin hydrochloride was generously gifted by Ranbaxy Research Labs (Gurgaon, India). PVA (both Ocular inserts of various ophthalmic drugs have been reported in the recent past [3] [4] [5] [6] to improve poor ocular bioavailability. The use of appropriate animal models [7] [8] [9] in the development of such ocular dosage forms have become essential for better understanding and advancement of existing knowledge. Many rabbit eye models have been reported for bacterial [10] [11] [12] , viral 13, 14 and fungal infections. However, very stringent guidelines issued by various regulatory agencies in using animals as experimental models have called for the need to develop in vitro models that could be viewed as a potential *For correspondence E-mail: jkpandit@bhu.ac.in high and low molecular weight) was obtained commercially from S. D. Fine Chemicals (Mumbai, India). The microbiological media were purchased from HiMedia Ltd. (Mumbai, India). All other reagents used were of analytical grade.
Preparation of ocular inserts:
The inserts were prepared by casting method with minor modification 15 . Solutions of PVA [different compositions of low (14 000) and high (125 000) molecular weights, Table  1 ] were prepared in boiling distilled water. The mixture was stirred for 20-24 h to get a clear solution. Then, glycerol (10% w/w, with respect to PVA) was added as plasticizer to the solution and stirred for further 3 h. www.ijpsonline.com the continuous flow of tears to a certain extent but the constant blinking action of the eye was not attempted to be simulated 16 . The design and working of the continuous flow-through apparatus is described elsewhere 16 .
In the drug release study, one insert was weighed and placed on the wire mesh support of the bottom plate. A Whatman filter paper circle (1 cm 2 area) was then placed over the insert, and the components of the unit were screwed together. The peristaltic pump, connected with thermostated buffer (37±0.2°) at a flow rate of 0. were analyzed spectrophotometrically for CPH content, PVAL -PVA of low molecular weight (14 000), PVAH -PVA of high molecular as described earlier. After 24 h of release study, the residual drug in the insert was determined by stirring the residual inserts in 10 ml buffer for 6 h, and the Weighed amounts of CPH were added after passing contents were filtered through G 2 filter and analyzed through #100 mesh sieve and stirred for 4 h to get a spectrophotometrically. uniform dispersion. The dispersion was then degassed and cast on glass substrate and dried at 50° for 18-20 h.
In vitro microbiological studies: The dried films were carefully removed and inserts of Suspensions of the test organisms S. aureus and P. dimensions 2 × 6 mm and average thickness of 0.2 mm aeruginosa were prepared so as to give 0. Uniformities of weight, thickness and drug nm. Aliquots of 1, 2 and 3 ml of the 0.5 McFarland equivalent suspensions of S. aureus ATCC 25923 and P. The thickness of six inserts was measured at three aeruginosa ATCC 27853 were inoculated into sterile different randomly selected spots of each insert with a peptone water, and the volume was made up to 5 ml with screw gauge. For uniformity of weight, 10 inserts from peptone water. The inserts were introduced into these each batch were weighed individually and their mean solutions, and the plugged tubes were incubated at 37°. At determined. For uniformity of drug content, 6 inserts from periodic time intervals, standard loopfuls from individual each batch were weighed individually and dissolved in 50 tubes were streaked on sterile nutrient agar plates and ml of 0.2 M phosphate buffer pH 7.4. The resultant incubated at 37° for 24 h and observed for growth. To solution was filtered through a G-2 glass filter. An aliquot account for the growing number of organisms in the
weight (125 000) standard at 625 content:
of the filtrate was suitably diluted and analyzed for CPH content at 272 nm (Shimadzu, UV-1601, Japan).
Surface pH:
Surface pH of the inserts was determined by allowing them to swell in a closed Petri dish at room temperature for 30 min in 0.1 ml of double distilled water. The swollen devices were removed and placed on pH paper to determine the surface pH. After 60 s the colour developed was compared with the standard colour scale.
In vitro release studies:
The inserts were evaluated for drug release kinetics by using a continuous flow-through apparatus, which mimics media at the initial times of drug release from the inserts, challenging was done at 3 h from the start of the study by further inoculation with 20% v/v of the initial inoculum of S. aureus or P. aeruginosa. Positive and negative controls were maintained throughout the study.
RESULTS AND DISCUSSION
The surface pH of the prepared inserts varied between 5.5 and 7.5, indicating that the inserts did not have an irritation potential 18 as the pH is within the accepted ocular range. The weight variation and thickness of the prepared inserts were within 2%. The drug content of the inserts varied from 95.96±1.14% to 99.67±1.03% for BPC 7 and BPC 14 respectively. www.ijpsonline.com
The release from the prepared inserts followed matrix diffusion kinetics in all cases, as evidenced by the regression coefficient (r 2 ) values, which were always higher for Q vs. t 1/2 (between 0.917 and 0.997) than for Q vs. t (0.774 to 0.936). Similar release kinetics was reported for flurbiprofen 19 and indomethacin 20 from PVA gels prepared by freeze-thawing and PVA disks respectively. However, the calculated diffusion coefficient (n) values ranged between 0.737 and 0.851, indicating the prevalence of an anomalous release behaviour / mechanism, which seems to be dependent on both matrix presence of lesser amount of the drug at the periphery with decrease in drug loading. Similar behaviour was observed from the batches containing PVAL ( fig. 1 ). The rate of release was however proportional to the drug loading, showing a significant increase with increase in drug loading.
Since not much difference was observed in the release profiles from either of the inserts (PVAL and PVAH), the matrix residue was weighed, after drying on tissue paper, at the end of the dissolution studies. The PVAH inserts swelling and erosion 21 . The minimal initial burst effect showed 35-38% reduction from their original weight, seen from the inserts ( fig. 1 ) containing both PVAL and while the PVAL inserts showed a reduction of 22-25%. PVAH in varying proportions could be attributed to the This was again indicative of the fact that the drug release more soluble nature of PVAH in comparison to PVAL.
was controlled by swelling /erosion of the matrix along Further, the amount of drug released increased with an with diffusion, which explained the independence of drug increase in the proportion of PVAH in the inserts.
release to drug loading. Perhaps, the presence of higher proportions of PVAH could have resulted in more pronounced matrix swelling
The plasticizer is the most important component that may and erosion. This was further confirmed by the fact that affect the mechanical properties of the films as it lowers the drug release from batches containing PVAH alone the glass-transition temperature 22 of the polymer. Hence, ) was significantly (P < 0.05, t-test) higher drug release from the plasticized insert (BPC than the corresponding batches containing only PVAL compared with the corresponding unplasticized insert ( fig. 2) . Similar results were reported for indomethacin (BPC 8 ). In these two batches, both PVAL and PVAH are ocular inserts containing different proportions of PVAH present in equal proportions, and any difference in the and PVAL 15 . The effects of three different drug loadings release pattern could be directly related to the presence were studied from inserts containing either PVAH or or absence of the plasticizer. PVA could be effectively PVAL. The release profiles of the inserts containing plasticized by a variety of plasticizers like PEG 200 and PVAH indicated that there was no significant difference 400, propylene glycol, glycerol, etc. In this study, glycerol between the amounts of drug released at the end of 24 at 10% concentration was selected as it gave sufficiently h. However, during the initial phases, a marked decrease pliable films to allow for uniform subdivision into inserts in the amount of released drug was observed with without breaking the film. The amount of drug released decrease in drug loading, presumably due to the from BPC 7 was significantly higher than the amount (BPC 1 to BPC 3 ) was www.ijpsonline.com released from the unplasticized insert (BPC 8 ). The presence of glycerol in BPC 7 enhanced the hydrophilicity of the PVA matrix. This in turn resulted in enhanced permeability of the inserts, resulting in enhanced swelling and the consequent increase in the porosity of the matrix, thus accounting for higher drug release.
S. aureus ATCC 25923, the most common ocular pathogen; and P. aeruginosa ATCC 27853, the most opportunistic ocular pathogen, were used as model When S. aureus was the organism, batches BPC 1 and BPC 4 containing 0.5 mg of CPH were effective in inhibiting the growth in all the tubes for 24 h, beyond which growth was observed in two tubes each at 30 and 48 h for batch BPC at inoculum volume of 2 and 3 ml. In 1 case of batch BPC 4 , growth was observed in one tube each at 48 h at an inoculum volume of 2 and 3 ml, indicating that the batch BPC 4 composed of only PVAL sustained the drug release more effectively than BPC 1 containing the same amount of PVAH. Decrease in the drug loading in the inserts composed of either of the organisms in the study. The 0.5 McFarland standard PVA did not produce any remarkable change in the suspensions of S. aureus and P. aeruginosa revealed a effectiveness of the inserts against the two count of 1.02×10 6 and 1.43×10 6 organisms/ml respectively. microorganisms. The antimicrobial effectiveness of the inserts was tested by varying the volume of the inoculum. The inserts were
The unplasticized insert (BPC 8 ) was unable to inhibit the more effective in inhibiting the growth of P. aeruginosa growth of S. aureus in all the tubes from the 24 th hour (at when compared to S. aureus (Table 2 , data shown for 30 3 ml inoculum level) onwards, whereas in contrast the and 48 h only). Challenging was done with 20% v/v of corresponding plasticized insert (BPC the initial inoculum size after 3 h to simulate the number growth of S. aureus in all the tubes for 30 h. This of growing organisms.
indicated the propensity of the plasticized insert to release higher amount of the drug due to the channelling effect of the plasticizer, resulting in faster and higher the study (48 h) when the inoculum volume was 1 ml. At
higher inoculum volumes (2 and 3 ml), the inserts were
unable to inhibit the growth in all the tubes, showing an
efficiency of 60-80% from the 24
Introduction of one more insert at the 24
have resulted in the inhibition of the growth in all the
tubes beyond the 24 th hour. In other words, and by 2 -5 -5 -5 -4 (+1) implication, the developed inserts have the potential of
once-a-day application in the treatment of ocular 2 hour would This study describes the complete methodology for the development of the CPH ocular insert, including the in vitro release studies on a flow-through apparatus and analysis of drug release kinetics. The studies also demonstrated the effectiveness of the prepared inserts against two of the most common ocular pathogens (S. aureus and P. aeruginosa). Further, the in vitro release data correlated well with the microbiological efficacy data without having to simultaneously use the rabbit eye model, which, in our opinion, is a substantial improvement over an earlier reported method 23 . These inserts have the potential to form the basis of a once-daily therapy of 
